Search
Thiotepa
go.drugbank.com/drugs/DB04572ApprovedInvestigationalIt is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. … N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 InhibitorsSynonyms: N,N′,N′′-tri-1,2-ethanediyl-, Phosphorothioic triamide, N,N′,N′′-tri-1,2-ethanediyl-Inbakicept
go.drugbank.com/drugs/DB16479InvestigationalInbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. It is one of the active ingredients in Anktiva, a combination product also containing nogapendekin alfa, where a single inbakicept is com...
Synonyms: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEINAdapalene
go.drugbank.com/drugs/DB00210ApprovedInvestigationalAcne vulgaris is a multifactorial disorder of the pilosebaceous unit involving increased sebum production, inflammation, and hyperproliferation/hyperkeratinization of the follicular infundibulum. It is also associated with Cutibacterium ...
Atorvastatin
go.drugbank.com/drugs/DB01076ApprovedInvestigationalAtorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduc...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesProducts: Nb-atorvastatin, ATORVASTATINA P-CAREFosnetupitant
go.drugbank.com/drugs/DB14019ApprovedInvestigationalIn April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alte...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesQuaternium-18
go.drugbank.com/drugs/DB11305ApprovedWithdrawnAcute oral and percutaneous toxicity tests in animals indicate that they exhibit little or no systemic toxic effects.
Lixisenatide
go.drugbank.com/drugs/DB09265ApprovedInvestigationalIt is sold by Sanofi-Aventis under the brand name Adlyxin in the US[L763] and Lyxumia in the EU.[L764] Adlyxin recieved FDA approval July 28, 2016.[L763]
Mixtures: SOLİQUA SOLOSTAR 100 U/ML + 33 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEM, SOLİQUA SOLOSTAR 100 U/ML + 50 MCG/ML SC ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR KALEM, 5 KALEMOliceridine
go.drugbank.com/drugs/DB14881ApprovedInvestigationalSevere acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors. Opioid receptors are seven-transmembrane G...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesPhosphoaminophosphonic Acid-Adenylate Ester
go.drugbank.com/drugs/DB04395ExperimentalAn analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors